Chronic Idiopathic Constipation — Management Guideline
Source: AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation — American Journal of Gastroenterology, 2023
Guideline: Strong
Guideline: Conditional
Guideline: Not recommended
ClinicoQ pathway suggestion (not from the cited guideline)
Diagnosis
Diagnostic criteria
Chronic idiopathic constipation is a disorder of gut-brain interaction causing infrequent and incomplete defecation without an identifiable mechanical or metabolic cause.
⚠ Alarm features (investigate before diagnosing)
- Rectal bleeding or a positive fecal occult blood test
- Unintended weight loss
- Iron deficiency anemia
- Family history of colorectal cancer or IBD
- New-onset constipation after age 50
- Palpable abdominal or rectal mass
Initial workup
| Test | When to order |
|---|---|
| Digital rectal exam | In all patients, to assess for structural causes or an evacuation disorder. |
| Colonoscopy | Alarm features present, or age-appropriate colorectal cancer screening is due. |
| Thyroid function, calcium, glucose | To rule out metabolic causes if clinically suspected. |
Treatment
First-line
1
Fiber supplementation (psyllium)
Conditional (Guideline recommendation) — especially with low dietary fiber intake
- Dose
- Start with a small daily dose, titrate up gradually
- Duration
- Ongoing
- Evidence level
- Low-Moderate
- Avoid if
- Bowel obstruction; severe bloating that worsens with fiber
- If no response ClinicoQ pathway
- Add an osmotic laxative
2
Polyethylene glycol (PEG)
Strong (Guideline recommendation)
- Dose
- 17 g (one capful) dissolved in water, once daily
- Duration
- Ongoing, reassess response
- Evidence level
- Moderate
- Avoid if
- Known or suspected bowel obstruction
- If no response ClinicoQ pathway
- Add a stimulant laxative as needed, or move to prescription options
If OTC options fail
1
Bisacodyl or senna (stimulant laxative)
Strong (Guideline recommendation), as adjunct or short-term therapy
- Dose
- Bisacodyl 5–10 mg at bedtime as needed
- Duration
- As needed or short-term use
- Evidence level
- Moderate
- Avoid if
- Bowel obstruction
- If no response ClinicoQ pathway
- Move to a prescription secretagogue
2
Linaclotide
Strong (Guideline recommendation)
- Dose
- 145 mcg once daily on an empty stomach (CIC dose — lower than the 290 mcg IBS-C dose)
- Duration
- Reassess at 4 weeks
- Evidence level
- Moderate
- Avoid if
- Known/suspected mechanical GI obstruction; not for patients under 6 years old
- If no response ClinicoQ pathway
- Try plecanatide or prucalopride
3
Prucalopride
Strong (Guideline recommendation)
- Dose
- 2 mg once daily (1 mg for patients over 65, renal impairment, or severe hepatic impairment)
- Duration
- Reassess at 4 weeks
- Evidence level
- Moderate
- Avoid if
- Mechanical GI obstruction
- If no response ClinicoQ pathway
- Refer for specialist GI evaluation
✕ Treatments the guideline advises against
PEG products for IBS-C symptoms (distinct from CIC): Guideline for IBS specifically does not recommend PEG for global IBS-C symptom relief (shown to help stool frequency but not abdominal pain) — PEG remains appropriate for plain chronic constipation as above.
⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.